Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in alzheimer's disease

Psychoneuroendocrinology

Volumn 38, Issue 9, 2013, Pages 1729-1737

  Johansson, Per ^a,b   Åberg, Daniel ^b   Johansson, Jan Ove ^b   Mattsson, Niklas ^b   Hansson, Oskar ^c   Ahrén, Bo ^d   Isgaard, Jörgen ^b   Åberg, N David ^b   Blennow, Kaj ^b   Zetterberg, Henrik ^b,e   Wallin, Anders ^b   Svensson, Johan ^b,f  

^a SKARABORG HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f SKARABORG HOSPITAL   (Sweden)

Author keywords

AD biomarker; Alzheimer's disease; Cerebrospinal fluid; IGF I; IGFBP 3; Insulin; Mild cognitive impairment

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; INSULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN CEREBROSPINAL FLUID LEVEL; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SCORING SYSTEM;

AD BIOMARKER; ALZHEIMER'S DISEASE; CEREBROSPINAL FLUID; IGF-I; IGFBP-3; INSULIN; MILD COGNITIVE IMPAIRMENT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DEMENTIA; FEMALE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; SINGLE-BLIND METHOD; TAU PROTEINS; WAIST-HIP RATIO;

EID: 84883656318     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2013.02.006     Document Type: Article

References (52)

1. Aberg D. Role of the growth hormone/insulin-like growth factor 1 axis in neurogenesis. Endocr. Dev. 2010, 17:63-76.
2. Aberg D., Jood K., Blomstrand C., Jern C., Nilsson M., Isgaard J., Aberg N. Serum IGF-I levels correlate to improvement of functional outcome after ischemic stroke. J. Clin. Endocrinol. Metab. 2011, 96:E1055-E1064.
3. Blackmore D., Vukovic J., Waters M., Bartlett P. GH mediates exercise-dependent activation of SVZ neural precursor cells in aged mice. PLoS ONE 2012, 7:e49912.
4. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:131-144.
5. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol. Chem. Neuropathol. 1995, 26:231-245.
6. Bondanelli M., Ambrosio M., Onofri A., Bergonzoni A., Lavezzi S., Zatelli M., Valle D., Basaglia N., degli Uberti E. Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. J. Clin. Endocrinol. Metab. 2006, 91:3928-3934.
7. Broughton S., Partridge L. Insulin/IGF-like signalling, the central nervous system and aging. Biochem. J. 2009, 418:1-12.
8. Busiguina S., Fernandez A., Barrios V., Clark R., Tolbert D., Berciano J., Torres-Aleman I. Neurodegeneration is associated to changes in serum insulin-like growth factors. Neurobiol. Dis. 2000, 7:657-665.
9. Carro E., Spuch C., Trejo J., Antequera D., Torres-Aleman I. Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. J. Neurosci. 2005, 25:10884-10893.
10. Carro E., Torres-Aleman I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur. J. Pharmacol. 2004, 490:127-133.
11. Carro E., Trejo J., Gomez-Isla T., LeRoith D., Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med. 2002, 8:1390-1397.
12. Cohen E., Paulsson J., Blinder P., Burstyn-Cohen T., Du D., Estepa G., Adame A., Pham H., Holzenberger M., Kelly J., Masliah E., Dillin A. Reduced IGF-1 signaling delays age-associated proteotoxity in mice. Cell 2009, 139:1157-1169.
13. de la Monte S. Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. J. Alzheimer's Dis. 2012, 30(Suppl. 2):S231-S249.
14. Donahue C., Kosik K., Shors T. Growth hormone is produced within the hippocampus where it responds to age, sex, and stress. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6031-6036.
15. Duron E., Funalot B., Brunel N., Coste J., Quinquis L., Viollet C., Belmin J., Jouanny P., Pasquier F., Treluyer J.-M., Epelbaum J., le Bouc Y., Hanon O. Insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Alzheimer's disease. J. Clin. Endocrinol. Metab. 2012, 97:4673-4681.
16. Erkinjuntti T., Inzitari D., Pantoni L., Wallin A., Scheltens P., Rockwood K., Roman G., Chui H., Desmond D. Research criteria for subcortical vascular dementia in clinical trials. Neural Transm. Suppl. 2000, 59:23-30.
17. Falleti M., Maruff P., Burman P., Harris A. The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature. Psychoneuroendocrinology 2006, 31:681-691.
18. Fernandez A., Torres-Alemán I. The many faces of insulin-like peptide signalling in the brain. Nat. Rev. Neurosci. 2012, 13:225-239.
19. Folstein M., Folstein S., McHugh P. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
20. Gil-Bea F., Solas M., Solomon A., Mugueta C., Winblad B., Kivipelto M., Ramirez M., Cedazo-Mínguez A. Insulin levels are decreased in the cerebrospinal fluid of women with prodomal Alzheimer's disease. J. Alzheimers Dis. 2010, 22:405-413.
21. Heuser I., Baronti F., Marin C., Merriam G., Chase T., Mouradian M. Growth hormone secretion in Alzheimer's disease: 24-h profile of basal levels and response to stimulation and suppression studies. Neurobiol. Aging 1992, 13:255-260.
22. Jogie-Brahim S., Feldman D., Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr. Rev. 2009, 30:417-437.
23. Johansson J.O., Larson G., Andersson M., Elmgren A., Hynsjö L., Lindahl A., Lundberg P.A., Isaksson O.G., Lindstedt S., Bengtsson B.A. Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters. Neuroendocrinology 1995, 61:57-66.
24. Johansson P., Mattsson N., Hansson O., Wallin A., Johansson J.O., Andreasson U., Zetterberg H., Blennow K., Svensson J. Cerebrospinal fluid biomarkers for Alzheimer's disease: diagnostic performance in a homogeneous mono-center population. J. Alzheimers Dis. 2011, 24:537-546.
25. Li L., Hölscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res. Rev. 2007, 56:384-402.
26. Liu Y., Liu F., Grundke-Iqbal I., Iqbal K., Gong C. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J. Pathol. 2011, 225:54-62.
27. López-Fernández J., Sánchez-Franco F., Velasco B., Tolón R., Pazos F., Cacicedo L. Growth hormone induces somatostatin and insulin-like growth factor I gene expression in the cerebral hemispheres of aging rats. Endocrinology 1996, 137:4384-4391.
28. Lopez-Lopez C., LeRoith D., Torres-Aleman I. Insulin-like growth factor I is required for vessel remodeling in the adult brain. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9833-9838.
29. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
30. Molina J., Jiménez-Jiménez F., Vargas C., Gómez P., de Bustos F., Gómez-Escalonilla C., Zurdo M., Tallón A., Martínez-Salio A., Porta-Etessam J., Villanueva C., Arenas J. Cerebrospinal fluid levels of insulin in patients with Alzheimer's disease. Acta Neurol. Scand. 2002, 106:347-350.
31. Mustafa A., Lannfelt L., Lilius L., Islam A., Winblad B., Adem A. Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation. Dement. Geriatr. Cogn. Disord. 1999, 10:446-451.
32. Nishijima T., Piriz J., Duflot S., Fernandez A.M., Gaitan G., Gomez-Pinedo U., Verdugo J.M., Leroy F., Soya H., Nuñez A., Torres-Aleman I. Neuronal activity drives localized blood-brain-barrier transport of serum insulin-like growth factor-I into the CNS. Neuron 2010, 67:834-846.
33. Ohlsson C., Mohan S., Sjögren K., Tivesten A., Isgaard J., Isaksson O., Jansson J., Svensson J. The role of liver-derived insulin-like growth factor-I. Endocr. Rev. 2009, 30:494-535.
34. Petersen R. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 2004, 256:183-194.
35. Petersen R., Smith G., Waring S., Ivnik R., Tangalos E., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 56:303-308.
36. Reinhardt R., Bondy C. Insulin-like growth factors cross the blood-brain barrier. Endocrinology 1994, 135:1753-1761.
37. Rivera E., Goldin A., Fulmer N., Tavares R., Wands J., de la Monte S. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J. Alzheimers Dis. 2005, 8:247-268.
38. Román G., Tatemichi T., Erkinjuntti T., Cummings J., Masdeu J., Garcia J., Amaducci L., Orgogozo J., Brun A., Hofman A., Moody M., O'Brien M., Yamaguchi T., Grafman J., Drayer B., Bennett D., Fisher M., Ogata J., Kokmen E., Bermejo F., Wolf P., Gorelick P., Bick K., Pajeau A., Bell M., DeCarli C., Culebras A., Korczyn A., Bogousslavsky J., Hartmann A., Scheinberg P. Vascular dementia: diagnostic criteria for research studies, Report of the NINDS-AIREN International Workshop. Neurology 1993, 43:250-260.
39. Russo V., Gluckman P., Feldman E., Werther G. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr. Rev. 2005, 26:916-943.
40. Salehi Z., Mashayekhi F., Naji M. Insulin like growth factor-1 and insulin like growth factor binding proteins in the cerebrospinal fluid and serum from patients with Alzheimer's disease. Biofactors 2008, 33:99-106.
41. Schrijvers E., Witteman J., Sijbrands E., Hofman A., Koudstaal P., Breteler M. Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology 2010, 75:1982-1987.
42. Steen E., Terry B., Rivera E., Cannon J., Neely T., Tavares R., Xu X., Wands J., de la Monte S. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7:63-80.
43. Talbot K., Wang H., Kazi H., Han L., Bakshi K.P., Stucky A., Fuino R., Kawaguchi K., Samoyedny A., Wilson R., Arvanitakis Z., Schneider J., Wolf B., Bennett D., Trojanowski J., Arnold S. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 2012, 122:1316-1338.
44. Tham A., Nordberg A., Grissom F., Carlsson-Skwirut C., Viitanen M., Sara V. Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J. Neural. Transm. Park. Dis. Dement. Sect. 1993, 5:165-176.
45. Tibbling G., Link H., Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand. J. Clin. Lab. Invest. 1977, 37:385-390.
46. Tong M., Dong M., de la Monte S. Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. J. Alzheimers Dis. 2009, 16:585-599.
47. Trejo J., Carro E., Torres-Aleman I. Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. J. Neurosci. 2001, 21:1628-1634.
48. van Himbergen T., Beiser A., Ai M., Seshadri S., Otokozawa S., Au R., Thongtang N., Wolf P., Schaefer E. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease. Arch. Neurol. 2012, 69:594-600.
49. Vanderstichele H., Van Kerschaver E., Hesse C., Davidsson P., Buyse M., Andreasen N., Minthon L., Wallin A., Blennow K., Vanmechelen E. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 2000, 7:245-258.
50. Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van Der Perre B., Sjogren M., Andreasen N., Blennow K. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 2000, 285:49-52.
51. Vardy E., Rice P., Bowie P., Holmes J., Grant P., Hooper N. Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. J. Alzheimers Dis. 2007, 12:285-290.
52. Watanabe T., Miyazaki A., Katagiri T., Yamamoto H., Idei T., Iguchi T. Relationship between serum insulin-like growth factor-1 levels and Alzheimer's disease and vascular dementia. J. Am. Geriatr. Soc. 2005, 53:1748-1753.